Cardiac Differentiation of iPSCs

Catalent scientists participate in an EU-funded initiative to establish a viable workflow for the scalable production of cardiomyocytes from iPSCs. A number of cardiac differentiation protocols have been published to date and several have been shown to enable efficiencies above 90%. However, many existing protocols are notoriously inconsistent in that they work or fail from experiment to experiment.

Similar observations were made by our scientists with a semi-optimized version of their newly developed protocol. However, a patent-pending modification to the media exchange schedule solved this issue (see above figure). Moreover, the methodology was designed to avoid infringement of competing IP and is scalable according to preliminary data, with the resulting cells showing maturation features such as a pronounced sarcomere structure over time.

As with the other platforms, talk to your Catalent representative about a partnering solution based on our in-house IP or, alternatively, leverage our expertise into your process development.